DIA 2023: Returning Patient Data

In an interview at the 2023 DIA annual meeting with ACT editor, Andy Studna, Jean Sposaro, program lead, TransCelerate BioPharma, and director, global drug development operations industry collaborations, Bristol Myers Squibb discusses key takeaways from a session she moderated, "Returning Individual Participant Data: A Cultural and Operational Shift Towards Personalized Clinical Trial Options." Sposaro also touches on the concept of "data dumping," which was brought up at the session by David Leventhal, enterprise clinical trial data sharing lead, global data dissemination, Pfizer.

A more in-depth recap of the session itself can be found here.